Minimize Uncertainty – Make Informed Decisions – Succeed

Cardiovascular

Cardiovascular Video Recap—January 15, 2026

January 15, 2026Camzyos,mavacamten,BioPharma and Tech News,aficamten,diabetes,Myqorzo,Atrial fibrillation,hypertension,Edwards Lifesciences,CABG,Cardiovascular News,mitral regurgitation,Cytokinetics,Stereotaxis,Acesion Pharma,YorLabsmitral annular calcification,Sapien M3

This Cardiovascular Video Recap covers major milestones, including…

by LucidQuest

Rare Disease news

Rare Disease Video Recap—January 15, 2026

January 15, 2026mitapivat,Zycubo,Immune thrombocytopenia,Copper histidinate,pfizer,Menkes disease,Fabry Disease,thrombotic stroke,Sickle Cell Disease,microcystic lymphatic malformations,BioPharma and Tech News,cutaneous venous malformations,Cushings Syndrome,Atara,BTK Inhibitor,Palvella,hypertension,Agios,Rilzabrutinib,Pegunigalsidase alfa,Thalassemia,Relacorilant,Rare Disease News,Hympavzi,Chiesi,Marstacimab,Corcept,Tabelecleucel,Wayrilz,QTORIN rapamycinElfabrio,Aqvesme

This Rare Disease Video Recap highlights major regulatory decisions and…

by LucidQuest

Cell_Gene_Therapy

Cell and Gene Therapy Today—January 15, 2026

January 15, 2026Duchenne Muscular Dystrophy,Huntington's disease,BioPharma and Tech News,Friedreich ataxia,Cell and Gene Therapy News,AAV Gene Therapy,CAR T cell therapy,CRISPR gene editing,FDA accelerated approvalRMAT designation,gene therapy manufacturing

This week’s Gene and Cell Therapy highlights key regulatory, clinical, and…

by LucidQuest

Cardiovascular

Cardiovascular Today—January 15, 2026

January 15, 2026BioPharma and Tech News,Atrial fibrillationEdwards Lifesciences,Cardiovascular News,Structural heart disease,agentic AI,cardiovascular-kidney-metabolic syndrome,coronary artery bypass grafting,TIMP-3 gene therapy,Haemonetics,intracardiac echocardiography

This Cardiovascular weekly update highlights key developments, spanning…

by LucidQuest

Rare Disease news

Rare Disease Today—January 15, 2026

January 15, 2026gene editing,Sickle Cell Disease,real-world evidence,BioPharma and Tech News,Friedreich ataxia,Thalassemia,Orphan Drug Designation,Rare Disease News,PhenylketonuriaMenkes disease,Aurora Therapeutics

This week’s Rare Disease update highlights major developments, spanning…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD

January 15, 2026clinical trials,Regulatory,immunology,biopharma,TL1A,Lucid Diligence Brief,payer access,diligence,venture financing,inflammatory bowel diseaseIL-23

Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……

by Timos Papagatsias

Immunology

Immunology Video Recap—January 14, 2026

January 14, 2026Johnson and Johnson,Cutaneous lupus erythematosus,Immune thrombocytopenia,astrazeneca,Halozyme,sanofi,MoonLake Immunotherapeutics,takeda,Royalty Pharma,BioPharma and Tech News,Teva Pharmaceutical Industries,TREMFYA,Vedolizumab,hidradenitis suppurativa,Entyvio,Rilzabrutinib,Anifrolumab,Immunology News,Saphnelo,InnoCare Pharma,Sonelokimab,guselkumab,Ethicon,inflammatory bowel disease,Bruton’s tyrosine kinase inhibition,Wayrilz,OTTAVA robotic surgical system,Systemic lupus erythematosus,SLK antibodyVitiligo,Paediatric plaque psoriasis

This Immunology video highlights major regulatory approvals, late-stage…

by LucidQuest

Immunology

Immunology Today—January 14, 2026

January 14, 2026Legacy Healthcare,10x Genomics,astrazeneca,Brigham and Women’s Hospital,takeda,Candid Therapeutics,BioPharma and Tech News,Vedolizumab,autoimmune diseases,Entyvio,Inflammatory Diseases,Anifrolumab,Dupilumab,Saphnelo,Immunology News,Auricular neurostimulation,inflammatory bowel disease,OTTAVA bioelectronic medicine platform,Systemic lupus erythematosus,Sonelokimab,Halozyme,Cinainu,Galvanic Health,MoonLake ImmunotherapeuticsRoyalty Pharma,Teva Pharmaceutical Industries

This week's Immunology update highlights key advances including late-stage…

by LucidQuest

Neuroscience

Neuroscience Today—January 14, 2026

January 14, 2026migraine,Alzheimer's Disease,Cell Therapy,Huntington's disease,BioPharma and Tech News,Parkinson's Disease,Brain Computer Interface,Neuroscience News,AAV Gene Therapyblood-brain barrier delivery,neurosymbolic AI

Today's neuroscience weekly update spotlights major advances spanning cell and…

by LucidQuest

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal

January 14, 2026clinical trials,market access,Alzheimer's Disease,Regulatory,neuroscience,biopharma,licensing,Blood–brain barrier,Lucid Diligence Brief,payer accessdiligence

Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…

by Timos Papagatsias

Obesity Weekly News

Obesity Today—January 13, 2026

January 13, 2026real-world evidence,BioPharma and Tech News,Tirzepatide,Eli Lilly,type 2 diabetes,Viking Therapeutics,GLP-1 receptor agonist,Arrowhead Pharmaceuticals,amylinRNAi therapeutics,Obesity News

This week's Obesity update highlights accelerating innovation in obesity and…

by LucidQuest

Endocrinology

Endocrinology Video Recap—January 13, 2026

January 13, 2026Continuous glucose monitoring technologies,Artificial intelligence diagnostics in diabetes,sanofi,Gene therapy for diabetes,Celltrion,Gastric cancer diagnostics,BioPharma and Tech News,Artificial intelligence imaging biomarkers,denosumab biosimilars,Biomarker qualification programs,Endocrinology News,Regulatory pathways for biomarker approval,Entera Bio,type one diabetes,Genprex,autoimmune diabetes,Samsung Bioepis,Medtronic Diabetes,Osteoporosis drug development,Bone mineral density biomarkers,Surrogate endpoints for bone disease trialsParathyroid hormone–based therapies,Insulin delivery systems

This Endocrinology video recap covers regulatory advances, biosimilar market…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.